OBJECTIVE To compare oral glyburide vs subcutaneous insulin in prevention of perinatal complications in newborns of women with gestational diabetes.
G estational diabetes is a major public health concern, and its rate is increasing worldwide.
1,2 Adequate treatment of women with gestational diabetes reduces fetal and maternal morbidity.
3 Insulin continues to be the American Diabetes Association-recommended first-line therapy and the only pharmacologic treatment approved by the US Food and Drug Administration. 4 The American College of Obstetricians and Gynecologists recommends not using glyburide as a first-choice pharmacologic treatment. 5 However, insulin is expensive and inconvenient because it requires several subcutaneous injections a day and careful management of dose adaptation. 6 Glyburide is a potential alternative treatment and, as an oral drug, is more acceptable to patients. Since the first randomized trial by Langer et al 7 showed that glycemic control is similar for the 2 treatments, glyburide has become a common additional pharmacotherapy for gestational diabetes in the United States, 2 while in Europe it is not used routinely. Meta-analyses [8] [9] [10] [11] [12] [13] and recent studies 14,15 question use of glyburide, reporting an increased rate of neonatal morbidities compared with insulin, especially macrosomia and hypoglycemia. However, because all randomized trials comparing glyburide with insulin used maternal glycemic control as the primary outcome, they were not optimally designed to investigate neonatal complications. 7, 8 The aim of the present study was therefore to compare glyburide and insulin for prevention of perinatal complications, especially because the American College of Obstetricians and Gynecologists recommends equivalence or noninferiority trials comparing oral agents with insulin. 5 The comparison was planned as a noninferiority test because glyburide is an oral pharmacotherapy for gestational diabetes and is more convenient for patients, with greater ease of administration and reduced costs.
Methods

Study Design and Patients
We performed a multicenter randomized noninferiority trial (the Insulin Daonil trial [INDAO] ) in 13 tertiary care university hospitals in France. Recruitment lasted from May 2012 to September 2016, and November 2016 was the end of patient follow-up. The trial protocol is available in Supplement 1 and the statistical analysis plan in Supplement 2. All patients provided written informed consent before enrollment. The trial protocol was approved by the ethics committee of the Poissy St-Germain Hospital. An independent data and safety monitoring committee periodically reviewed study outcomes. Women with a singleton pregnancy who were diagnosed as having gestational diabetes between 24 and 34 weeks of gestation were eligible. Gestational diabetes was diagnosed if a 75-g oral glucose tolerance test resulted in 1 or more abnormal blood glucose values: greater than 92 mg/dL (5.1 mmol/L), greater than 180 mg/dL (10 mmol/L), or greater than 153 mg/dL (8.5 mmol/L) for fasting, 1-hour postprandial, or 2-hour postprandial blood glucose concentration, respectively. 16 Exclusion criteria were diabetes, fasting blood glucose concentration greater than 126 mg/dL (7 mmol/L), glucose screening test performed before 24 weeks of gestation, multiple pregnancy, chronic hypertension, preeclampsia, and known liver or renal disease.
Women diagnosed with gestational diabetes were given individual nutrition education by a dietitian designed to provide 25 kcal/kg per day for overweight and obese women and 35 kcal/kg per day for women at normal weight. Nutritional intake was divided into 3 meals and 2 snacks daily. Women were taught to self-monitor capillary blood glucose levels 4 times daily (fasting and 2 hours after each meal). Glycemic goals were considered not achieved after 10 days of well-managed diet if at least 2 blood glucose values above the targets were observed over a week (fasting: ≥95 mg/dL; 2-hour postprandial: ≥120 mg/dL), with no variations in diet. Women who did not meet glycemic goals were eligible for randomization to 1 of the 2 treatment groups.
Randomization
Eligible women were randomly assigned in a 1:1 ratio to receive glyburide or insulin. An independent, centralized, computer-generated randomization sequence (CleanWeb, Tele-medicine Technologies) was used for this allocation according to a permuted-block method with block sizes randomly chosen from 2 to 8, stratified by center. Clinicians and participants had no access to the list but could not be blinded to group allocation after randomization.
Procedures
For glyburide, the starting dosage for therapy was 2.5 mg orally once per day and could be increased if necessary 4 days later by 2.5 mg and thereafter by 5 mg every 4 days in 2 doses, morning and evening, up to a maximum of 20 mg/d. If the maximum tolerated dosage was reached without achieving the desired glucose values of less than 95 mg/dL (5.3 mmol/L) for fasting measurements and less than 120 mg/dL (6.7 mmol/L) for 2-hour postprandial measurements, treatment was switched to insulin.
For insulin, the starting dosage for rapid analogs was 4 IU given subcutaneously before meals, 1 to 3 times per day as necessary and increased by 2 IU every 2 days according to the postprandial blood glucose value. If necessary, the starting dosage for basal or intermediate insulin was 4 IU to 8 IU given subcutaneously at bedtime and increased by 2 IU every 2 days according to the morning fasting blood glucose value. Women were taught to self-adjust their insulin doses in an effort to reach and maintain glycemic goals throughout pregnancy.
All women had a clinical assessment with a visit to an endocrinologist at days 8 and 21 after randomization and then every 15 days to once per month according to level of glycemic control. In addition to these planned visits, women received prenatal care at their institutions as deemed appropriate by their caregivers (eg, general physicians, obstetricians, midwives). Newborn monitoring was identical to the usual recommendation for newborns of mothers with diabetes, with early and frequent breast or bottle feeding: from birth, at 30 minutes and then every 2 or 3 hours. Neonatal glucose monitoring started immediately after birth and included frequent measurements (8 in the first 24 hours and 2 on day 2). The number of glucose measurements was increased when clinically required.
Outcome Variables
The primary outcome was a composite criterion of perinatal complications associated with gestational diabetes, including macrosomia, neonatal hypoglycemia, and hyperbilirubinemia. Macrosomia was defined as birth weight greater than 4000 g or above the 90th percentile for gestational age according to French curves. 17 Neonatal hypoglycemia was defined as blood glucose value less than 36 mg/dL (2 mmol/L) after 2 hours of life. 18 Hyperbilirubinemia was defined as the need for phototherapy without another cause of jaundice. The prespecified secondary outcomes included (1) neonatal outcomes of perinatal death, admission to a neonatal intensive care unit (NICU) and neonatal ward, respiratory distress syndrome, birth injury, ponderal index (calculated as [birth weight in grams divided by height in centimeters cubed] times 100), pH level of less than 7, lactates in 3 categories (<6 mmol/L, 6-9 mmol/L, and >9 mmol/L), and base excess (not recorded); (2) maternal outcomes of glycemic control during pregnancy (see below), hypoglycemia (defined as blood glucose level <60 mg/dL [3.3 mmol/L]) and/or a symptomatic episode of hypoglycemia with clinical symptoms of severity (confusion, poor coordination, double vision, convulsion, or inability to self-treat symptoms), premature delivery, mode of delivery, perineal trauma, percentage switch from glyburide to insulin, and maternal satisfaction; and (3) other outcomes, data for which are not presented here, including number of prenatal visits, number of diabetologist visits, and hospitalization days during pregnancy.
Glycemic control during pregnancy was quantified for each woman by the percentage of blood glucose measurements at 95 mg/dL or greater for fasting measurements and 120 mg/dL or greater for 2-hour postprandial measurements. Three categories were defined (separately for fasting and postprandial measurements): good glycemic control (<20%), moderate or fairly good glycemic control (20%-40%), and poor glycemic control (>40%). A satisfaction questionnaire was given to women in the first postpartum week to assess treatment acceptability.
Additional outcomes considered exploratory were components of the primary composite outcome, characteristics of the newborn (birth weight, Apgar score, severity of hypoglycemia), reasons for admission to the NICU, mean insulin or glyburide dosages received by women, and severe episodes of maternal hypoglycemia (defined as glucose level <40 mg/dL).
Sample Size
We estimated the usual frequency of the primary outcome (macrosomia, hypoglycemia, and hyperbilirubinemia) in newborns of women with gestational diabetes treated with insulin to be 18% based on published randomized trials comparing insulin vs either usual prenatal care 3, 19 or glyburide treatment 7,20-23 and based on (unpublished) retrospective data from the participating centers. The noninferiority boundary was based on clinical evidence. 24 We asked a group of clinicians to consider what increase in neonatal complications they would accept in exchange for the potential benefits offered by glyburide. 25 They estimated that a 25% rate of perinatal complications in the glyburide group was acceptable. Glyburide was then considered noninferior to insulin if the upper confidence limit of the difference did not exceed the prespecified noninferiority margin of 7%. With these assumptions and with a statistical power of 80%, a type I error of 5%, and a 2-sided test, 372 women per group were required. With anticipation that approximately 20% of patients in the glyburide group would be switched to the insulin group, 26 450 women per group were necessary. 
Statistical Analysis
Continuous variables were summarized as means and standard deviations or medians and interquartile ranges if nonnormally distributed and qualitative variables as numbers and percentages of participants. To take into account that the trial was multicenter, mixed-effects models were used to compare the 2 groups (logistic for qualitative variables and linear for quantitative variables). These models were used to estimate means and standard deviations or percentages in each group and differences in means or percentages and 95% confidence intervals between groups.
Primary Outcome
The analysis of the primary outcome was performed on the per-protocol population excluding women who were switched from glyburide to insulin treatment comparing the difference (glyburide rate − insulin rate) in the frequency of the primary outcome.
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Noninferiority of glyburide compared with insulin was demonstrated if the upper bound of the 1-sided 97.5% confidence interval of this difference was smaller than the prespecified threshold of 7%.
A prespecified sensitivity analysis for women who switched treatment was performed on the intention-to-treat population. A complementary prespecified analysis was performed by adjusting for baseline characteristics that differed between randomized groups.
Secondary Outcomes
Analyses of secondary outcomes and post hoc analyses were made with superiority tests and 95% CIs for differences and should be considered exploratory because no correction for multiple comparisons was done.
No imputation was made for missing data because there were only 2 missing data for the primary outcome and very few for secondary outcomes. Complete case analyses were done. The threshold for statistical significance was set at P<.05 with a 2-sided test; for the primary outcome, a 1-sided 97.5% confidence interval was considered. Statistical analyses were performed using Stata software, release 14.
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Results
Characteristics of the Women
Among 914 women with gestational diabetes (mean age, 32.8 [SD, 5.2] years), 460 were randomized to receive glyburide treatment and 454 to receive insulin treatment. After randomization, 18 patients (2.0%) were excluded from the analysis because they did not meet the inclusion criteria and 6 because they had no data for the primary outcome or refused the treatment (Figure) . Among the 448 women remaining in the glyburide group, 81 (18%) were switched to insulin, most often before reaching the maximum glyburide dosage. The per-protocol analysis therefore included 809 women and their neonates, 367 in the glyburide group and 442 in the insulin group (Figure) .
The baseline characteristics of the 809 included women are shown in Table 1 . Overall, there were no noticeable between-group differences in demographic variables or blood glucose values at inclusion. Multiparity was more frequent in the insulin group (66.3% vs 58.9%), and gestational age at treatment was slightly greater in the glyburide group.
Primary Outcome
The frequency of the primary outcome was 27.6% in the glyburide group and 23.4% in the insulin group (difference, 4.2%; 1-sided 97.5% CI, −ϱ to 10.5%; P = .19), and the upper confidence limit exceeded the noninferiority margin of 7% (Table 2) . When adjusted for multiparity and gestational age at treatment, the results remained similar (difference, 4.4%; 1-sided 97.5% CI, −ϱ to 10.5%; P = .20) (eFigure in Supplement 3). b For each woman, the number of abnormal blood glucose assay results over all of her blood glucose assays between inclusion and randomization was computed, then medians and IQRs of these proportions were calculated.
Intention-to-treat sensitivity analysis indicated a difference of 4.2% (1-sided 97.5% CI, −ϱ to 10.0%; P = .17) (eTable 1 in Supplement 3).
Prespecified Secondary Neonatal Outcomes
No perinatal deaths occurred in the glyburide group, and there were 2 in the insulin group (1 patient with unexplained intrauterine death at 40 weeks of gestation with birth of an infant weighing 3400 g; 1 medical termination of pregnancy performed at 36 weeks of gestation because of severe brain abnormalities).
The rates of admission to an NICU and neonatal nursery did not differ significantly in the 2 groups. There were no significant between-group differences in birth injury, ponderal index, pH level of less than 7, lactate levels, and respiratory distress syndrome (Table 2) . .6%-34.0%; P < .001). There were no significant between-group differences in mode of delivery, preterm delivery, and perineal trauma. Overall, 68.5% of women completed the satisfaction questionnaire during their maternity stay. There was no significant relationship between nonresponse and the composite criterion (P = .82). In terms of maternal satisfaction, 23.6% of patients in the insulin group indicated that therapy is the most difficult part of the treatment, whereas only 5% did in the glyburide group (P < .001). Among women treated with glyburide, 78.7% indicated that they would choose glyburide treatment in a subsequent pregnancy, whereas only 19.9% of women treated with insulin would choose insulin again (P < .001) ( Table 2) .
Post Hoc Analyses
Per-protocol analysis results for the components of the composite criterion are given in Table 3 (and in eTable 2 in  Supplement 3 for the intention-to-treat analysis). Hypoglycemia occurred in 12.2% of the glyburide group and in 7.2% of the insulin group (difference, 5%; 95% CI, 0.5%-9.5%; P = .02). There were no significant between-group differences in macrosomia and hyperbilirubinemia rates.
Severity of hypoglycemia among newborns did not differ significantly between the groups, with blood glucose levels of 1 mmol/L or lower among 2 newborns in the glyburide group and 3 newborns in the insulin group. No neonate presented with severe clinical signs of hypoglycemia. Among newborns admitted to the NICU, none were admitted because of clinical signs of hypoglycemia or for treatment of hypoglycemia.
More women in the glyburide group had a severe hypoglycemia episode (blood glucose level <40 mg/dL: 13 [3.8%] in the glyburide group vs 4 [1.0%] in the insulin group; difference, 2.8%; 95% CI, 0.2%-5.5%; P = .02). Among them, 2 women in the glyburide group and 1 woman in the insulin group reported symptoms with an inability to self-treat their symptoms.
Discussion
This study of women with gestational diabetes failed to show that use of glyburide compared with subcutaneous insulin does not result in a greater frequency of perinatal complications. These findings do not justify use of glyburide as a firstline treatment.
The higher rate of the primary outcome in the glyburide group was mainly due to an increased rate of neonatal hypoglycemia. This is consistent with results of meta-analyses including observational studies and randomized trials. [8] [9] [10] [11] [12] [13] However, most of these meta-analyses also mention a significantly increased risk of macrosomia 8,9,11 in neonates of women treated with glyburide, and 2 studies using large administrative databases have additionally reported an increased risk of respiratory distress syndrome and NICU admissions with glyburide. 14, 15 These findings are not consistent with the results, albeit exploratory, reported in Table 3 , because no significant between-group differences were found in the rates of macrosomia, hyperbilirubinemia, admission to the NICU or neonatal nursery, or respiratory distress syndrome. An isolated increase in neonatal hypoglycemia in the glyburide group is in agreement with data from the Because women had gestational diabetes, study physicians knew the infants were at risk of hypoglycemia, and neonatal glucose was monitored frequently after birth, so it is unlikely that there were neonates with unrecognized and untreated hypoglycemia. The 18% glyburide-to-insulin switch rate is consistent with literature reports.
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The strengths of the present study include that it was a multicenter study, which increases its generalizability. In addition, a neonatal criterion was chosen as the primary outcome because, to our knowledge, no previous randomized trials have optimally assessed the potential effect of glyburide on prevention of perinatal complications.
7,20-23
Limitations
This study had several limitations. First, some criteria were not prespecified in the initial protocol, such as the components of the primary outcome or the reason for admission to the NICU, and these must therefore be considered as exploratory or post hoc analyses and are of reduced weight. Second, criteria chosen to assess satisfaction in terms of women's treatment preferences for a future pregnancy may be questioned, inasmuch as each woman received only 1 of the 2 treatments and had no experiential basis for making such a comparison.
The noninferiority framework provides, on one hand, a binary conclusion (significant or not) and, on the other hand, a more quantitative result with the boundaries of the 95% confidence interval.
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Although the data do not allow a conclusion that glyburide is not inferior to insulin in the prevention of perinatal complications, the results suggest that the increase in complications may be no more than 10.5% compared with insulin. This result should be balanced with the ease of use and better satisfaction with glyburide. In clinical situations in which an oral agent may be necessary, mothers, informed by their physicians, would be appropriate decision makers based on their own weighing of benefits and risks.
Conclusions
This study of women with gestational diabetes failed to show that use of glyburide compared with subcutaneous insulin does not result in a greater frequency of perinatal complications. These findings do not justify the use of glyburide as a firstline treatment. 
Research Original Investigation Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications in Gestational Diabetes
Version no. The second trial [12] , the aim of which was to evaluate the efficacy of active treatment of moderate 223 gestational diabetes, included 958 women at between 24 and 30 weeks of gestation with blood glucose of 224 between 1.35 and 2.00 g/L (7.5 mmol/L and 11 mmol/L) 1 h after 50 g of glucose and a 100-g OGTT with fasting 225 blood glucose <0. hyperinsulinism, and neonatal trauma (32.4% and 37% in the intervention and control groups, respectively; 233 p=0.14). In the intervention group, there were significant decreases in the frequency of macrosomia (5.9% 234 versus 14.3%), children of birth weight >90 th percentile (7.1% versus 14.5%), and shoulder dystocia (1.5% 235 versus 4.0%). 236
Active treatment comprising dietary management, blood glucose self-monitoring, and insulin treatment, if 237 necessary, is therefore beneficial in the treatment of gestational diabetes. 238
Insulin therapy 239
Insulin therapy is currently the reference therapeutic strategy used to manage gestational diabetes when 240 blood glucose targets are not achieved by dietary management alone. One of insulin's advantages is that, 241 because of its high molecular weight (6000 Da), it does not cross the placental barrier and so in theory there are 242 no fetal or neonatal side effects. 243
Although of proven efficacy [8, 12] , insulin treatment has several drawbacks. It is inconvenient as it 244 generally requires 4 and sometimes 5 subcutaneous injections a day. It also requires appropriate training on 245 how to perform injections and on capillary blood glucose monitoring 4 to 6 times a day. There is often a need for 246 endocrinologists to adjust the treatment with, if necessary, short hospitalization. And, lastly, insulin treatment is 247 expensive, because of the restrictions related to its use, and involves a risk of maternal hypoglycemia. 248
Oral antidiabetics and glyburide 249
Alternatives to oral antidiabetics have been envisaged for some years. Although they cross the placenta, 250 biguanides (Metformin®) have no long-term effects on the fetus, but they are effective on blood sugar balance in 251 only 54% of cases, meaning that they are of little value as an alternative to insulin therapy [15] . Published data on pregnant women exposed to glyburide during the first trimester are scarce, but no 286 malformation has been recorded to date. Glyburide is not teratogenic in animal studies.
-Fetal and neonatal effects 288
Published data on the second and third trimesters are numerous and no particular neonatal effect has been 289 noted in newborns. These data essentially concern gestational diabetes.
-Treatment of pregnant women 291
If the specialists managing the patient deem it relevant, the use of glyburide can therefore be envisaged, 292 particularly during the second and third trimesters. When treatment continues to term, neonatal blood glucose 293 will be monitored on principle. 294 -Discovery of pregnancy during treatment
295
Reassure the patient regarding the risk of malformation associated with glyburide (meaning that glyburide does 296 not increase the baseline 2% to 3% risk of malformation in any pregnancy. The discovery of pregnancy in a 297 diabetic woman calls for appropriate multidisciplinary management. 298
Results of studies of glyburide 299
Observational studies 300
Nonrandomized retrospective or prospective studies comparing the effects of insulin and glyburide in the 301 treatment of the gestational diabetes (Table 1) show that glyburide is effective in achieving glycemic control, 302 with a nonsignificant between-group difference in fasting and postprandial blood glucose. Only the study by 303 Jacobson et al shows that fasting and postprandial blood glucose targets were reached more often in the 304 glyburide group than in the insulin group (86% versus 63% p<0.001), including after adjustment for body mass 305 index, ethnicity, fasting blood glucose, and gestational age at diagnosis. In this study by Jacobson et al, which is 306 the largest numerically, glyburide was not significantly associated with a risk of macrosomia, birth weight >90 th 307 percentile for gestational age, hypoglycemia, or hyperbilirubinemia, compared with insulin. 308 criteria were not always reported in these studies (Table 2) . Also, the calculation of the number of subjects 328 needed and the main outcome were not always specified. pointed out that not all trials reported neonatal variables of interest, so this meta-analysis had insufficient power 367 to detect any differences in neonatal complications between the 2 treatments. 368
Description of the study population 369
The study population will comprise pregnant women who develop gestational diabetes between 24 and 34 370 weeks of gestation. Only singleton pregnancies will be included as the screening thresholds for gestational 371 diabetes for twin pregnancies are unknown. Patients with diabetes prior to pregnancy, patients diagnosed with 372 diabetes before 24 weeks of gestation, and patients with an initial diagnosis of diabetes with a fasting blood 373 
Trial length and feasibility 399
Our study will require 450 women per group (see section 10.2 for the calculation of the number of subjects 400 needed). Because an estimated 1.5% of pregnant women with gestational diabetes require drug treatment, 60 401 000 pregnant women will be necessary. Assuming that one in 2 women will agree to randomization, we need a 402 population of 120 000 pregnant women. As all participating maternity units manage about 40 000 deliveries a 403 year, recruitment can be achieved in 3 years. 404
Assumption 405
We assumed that glyburide is not inferior to insulin in treating gestational diabetes. 406
Primary objective 407
To test whether oral glyburide is not inferior to subcutaneous insulin in terms of perinatal complications in 408 treating pregnant women with gestational diabetes requiring treatment other than dietary management. 409
Secondary objectives 410
The secondary objectives of the INDAO trial are to demonstrate the noninferiority of glyburide compared 411 with insulin in terms of maternal blood sugar balance, rate of cesarean section, rate of premature delivery, 412 perinatal mortality rate, rate of neonatal and maternal trauma associated with delivery, rate of respiratory 413 distress, number of prenatal visits, number of days of hospitalization. Maternal satisfaction regarding the 2 drugs 414 will be evaluated. 415
Primary outcome 416
The primary outcome (see also section 5. The secondary outcomes (see section 5.1) include maternal criteria (blood sugar balance, conditions of 424 delivery, satisfaction) and neonatal criteria. 425
Methodology 426
INDAO is a clinical, noninferiority, multicenter, open, randomized, balanced trial. 427
Experimental plan -practical considerations 428
Study procedure 429
The patients will be recruited among women with gestational diabetes diagnosed by hyperglycemia (75 g  430 The WHO 75-g OGTT will be favored as it is recommended in the French 2010 RPC (clinical practice 437 guidelines) for gestational diabetes. However, the 2 screening tests will be possible to enable new practices to 438 be integrated into some maternity units and so as not to limit patient recruitment in departments where the O' 439 Sullivan test is still used for screening. As the inclusion criterion is failure to achieve blood glucose targets after 440 10 days of dietary management and the randomization will be done afterwards, the patients will be comparable 441 regardless of the screening test used. 442
The women will initially be treated by dietary management adapted to their individual needs evaluated by 443 means of an interview. Dietary intake will be 35 kcal/kg for non-obese patients, divided into 3 meals and 2 444 snacks, with approximately 40% to 45% of calories provided by carbohydrates, 20% by proteins, and 30-40% by 445 fats. Dietary intake will be 25 kcal/kg in obese patients defined by a BMI >30 kg/m 2 . This diet will be combined 446 with encouragement to do exercise equivalent to 30 min of walking 3 to 5 times per week, if the patient's 447 obstetrical condition allows. The patients will be educated concerning self-monitoring of blood glucose using 448 glucose meters, which should have a searchable memory and comply with standard ISO 15197. During the diet, 449 monitoring will be set up as a function of the centers: self-monitoring of capillary blood glucose (4 times/day) or, 450 after 10 days, fasting blood glucose and blood glucose 2 h after a meal. 451 452
Patients eligible for randomization between the 2 treatments will be those whose blood glucose target is 453 not reached, ie, those for whom at least 2 abnormal blood glucose values are recorded in one week: fasting 454 blood glucose 0.95 g/L and/or postprandial blood glucose at 2 h 1.20 g/L after 10 days of well-conducted 455 dietary management. In cases where there is an unusual departure from the diet, the blood glucose value 456 following the meal in question will not be taken into account. 457 458
Prior to the study, the patients will be informed about it and its procedures, and their written consent will 459 be collected. 460 461
The randomization between glyburide and insulin will be performed in each center, by the obstetrician or 462 the diabetologist, depending on the center's organization, using the randomization module of the application 463 CleanWEB  (Telemedicine Technologies). The patient will be managed by the diabetologist and the obstetrician 464 in terms of treatment initiation, education, and monitoring of treatment and of capillary blood glucose. 465
The insulin and glyburide regimens will be adapted as a function of the patients' blood glucose profiles 466 and the centers' habits regarding insulin therapy. In the 2 groups, a protocol for drug dose adjustment as a 467 function of capillary blood glucose will be given to the patient, who will adapt the doses by performing 4 capillary 468 blood glucose measurements per day: fasting in the morning and 2 hours after each meal. These blood glucose 469 values will be entered in a monitoring notebook and will be available in the memory card readers. If the blood 470 glucose targets are not achieved after a diet associated with maximum doses of glyburide over 1 week, the 471 treatment will be replaced by insulin. If the diabetes is balanced and there are no complications, there will be no 472 need to change obstetrical management. If gestational diabetes is unbalanced or has an effect on the fetus, 473 delivery will be induced, taking into account the risk-benefit ratio. 474
In the framework of their usual treatment, the newborns will have a routine pediatric examination at birth, 475 with measurement of weight, body length, and cranial circumference, and in the first 3 days of life. They will also 476 undergo routine monitoring of capillary blood glucose and screening for jaundice. 477 478
Patient follow-up 479
Timeline and content of visits 480 Randomization and treatment initiation will be done in hospital or in the outpatient department, depending 481 on the center's organization, at which time the obstetrician or diabetologist will collect the mother's consent. An 482 appointment will be made with a diabetologist one week after randomization, and then at least every 2 weeks, 483 and then, when the blood glucose target is reached and stable, every month until delivery, all this within the 484 framework of the usual follow-up of pregnant women with gestational diabetes. Between these appointments, 485 the patients can themselves increase the dose, as a function of capillary blood glucose readings, in line with the 486 dose adjustment protocol given to the patient at the first appointment. Between these appointments, the patients 487 in each center can, should they wish, have a telephone appointment or an email exchange if they have 488 questions or doubts. 489
At each visit, capillary blood glucose values in the monitoring notebook or in the memory card reader will 490 be analyzed. If the target is not reached, the diabetologist will increase the dose. In the event of hypoglycemia 491 (<0.6 g/L) or symptomatic hypoglycemia, doses will be decreased to the level below. The content of these visits 492
will not differ from that of the usual appointments for management of patients with gestational diabetes in the 493 participating maternity units. At these appointments, checks will be made for the presence of side effects or 494 adverse events. 495
Clinical follow-up of patients will be noted by the clinical research technician and/or the investigator in the 496 electronic case report form (e-CRF) provided for the purpose. Also noted will be pregnancy characteristics, 497 gestational age at diagnosis, and the dose of insulin or glyburide. At birth and in the days afterwards, the 498 following will be recorded: 499
 gestational age at delivery 500  method of delivery 501 and, if the informed parents do not refuse: 502  the child's birth weight, body length, and cranial circumference 503  pH and/or cord blood lactate at birth 504  5-minute APGAR score 505  all endpoints 506  any reasons for discontinuation or change of treatment 507 508
Monitoring of newborns 509
Monitoring will be identical to that generally recommended for the newborns of diabetic mothers: 510 -Weighing of children from birth 511 -Measurements: body length and cranial circumference 512 -Plotting of birth weight on growth curves [42] 
513
-Early and frequent feeding from birth: breastfeeding and/or bottle feeding from 30 min of life and every 2 h or 514 3 h. 515 -Measurement of capillary blood glucose before the first breastfeed, then before the second meal, then every 3 516 hours; before feeding for asymptomatic newborns. Capillary blood glucose must be measured using a reader 517 adapted to the characteristics of the newborn. Hypoglycemia must be checked by sending a blood sample 518 collected in a fluoropolymer tube to the laboratory. 519 -The presence of abnormal clinical signs is an indication for blood glucose measurement whenever these signs 520 are observed. 521 -If 2 consecutive capillary blood glucose values are between 45 mg/dL and 54 mg/dL (2.5 mmol/L and 3 522 mmol/L), measurements can be made every 6 hours and stopped after 24 hours if the blood glucose values are 523 normal and if the newborn is feeding normally. 524 -Hypoglycemia will be corrected in accordance with the local protocol. 525 -Jaundice will screened for in accordance with the local protocol and its severity will be assessed using a 526 bilirubin meter and/or a blood bilirubin test. The indications for phototherapy will be drawn up using the blood 527 bilirubin curves usually applied in the department concerned, as a function of gestational age, term of delivery, 528 and birth weight. This monitoring will not differ from that of infants born to mothers with gestational diabetes. 529 530
Procedures, examinations, and samples collected at visits 531
In patients included in the trial, apart from randomization and allocation of insulin or glyburide, no specific 532 procedure and no additional examination will be done for research purposes. 533 534
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Study sites 535
The INDAO trial will essentially be conducted during appointments. An outpatient visit will be possible at 536 some centers at initiation of treatment or when the diabetes is difficult to balance in the framework of usual 537 follow-up. 
Steps taken to minimize bias 549
Randomization 550
Treatments will be allocated by means of centralized balanced randomization (randomization module of 551 the application CleanWEB  , Telemedicine Technologies). The randomization list (insulin versus glyburide) will 552 be drawn up by the statistician Mrs Armelle Arnoux of the Paris Sud clinical research unit, using reference 553 software (eg, NQuery Advisor®), after agreement by the study scientific director. The randomization will be 554 stratified by center and by blocks of random size. After the patient signs the consent form, the investigator will 555 record the inclusion data in the e-CRF (CleanWEB  , Telemedicine Technologies), which will enable access to 556 the CleanWEB  randomization module. A single number will be attributed to each patient. The use of this e-557 CRF directly accessible via the Internet will facilitate the interaction between the maternity units, the 558 participating diabetology departments, and the various study participants. 559
Subjects who subsequently drop out will keep their inclusion number, if given one, and new subjects will always 560 receive a new inclusion number. The patients will therefore be identified by an alphanumeric code in the form of 561 "center number (3 characters) -center inclusion number (3 characters) -initials of the name and first name (1 562 and 1 characters)." 563
Blinding and methods used for its maintenance and code break procedure 564
The 2 treatments have different routes of administration and so blinding will not be used. 565
Dosage and mode of administration of the experimental drug 566
Glyburide will initially be taken in a single oral dose of 2.5 mg/day before breakfast. Dose increases will be 567 incremental as a function of blood glucose values up to a maximum total dose of 20 mg/day, until blood glucose 568 targets are reached (fasting blood glucose <0.95 g/L and postprandial blood glucose at 2 h <1.20 g/L). An 569 algorithm for dose adaptation depending on capillary blood glucose values will be given to the patient at the 570 instruction session. In the event of at least 2 abnormal values (fasting blood glucose 0.95 g/L and/or 571 postprandial blood glucose at 2 h 1.20 g/L), the dose will be increased by the patient at D4 to 5 mg in the 572 morning. At D8, the patient will have a review appointment with the diabetologist. If there are still 2 abnormal 573 values, the dose will be increased to 5 mg in the morning and 5 mg in the evening before dinner. At D12, if there 574 are still 2 abnormal values, the patient will increase the dose to 10 mg in the morning and 5 mg in the evening, 575 up to a maximum dose of 10 mg in the morning and 10 mg in the evening at D16. If there is a deviation from the 576 usual diet, the blood glucose value following the meal in question will not be taken into account. 577
The patient will have a diabetology appointment on D21: switch to insulin if the blood glucose targets are not 578
reached. The patient can use monitoring by telephone or by email at D4, D12 and D16 or if she experiences 579 side effects between appointments. In cases of symptomatic hypoglycemia or of blood glucose <0.6 g/L, the 580 glyburide dose will be decreased or returned to the previous level. Treatment will be continued until delivery. 581
Description of the experimental drug 582
Glyburide 583
Glyburide is marketed as Daonil® scored 5 mg tablets by Sanofi-Aventis France, which has the marketing 584 authorization. Treatments will be labeled by the Clinical Trials Unit of the Agence Générale des Equipements et 585
Produits de Santé (AGEPS; medicines and healthcare products regulatory agency) with the regulatory texts for 586 drugs used in clinical trials. Removable labels will be attached to the boxes, to ensure the traceability of 587 dispensing. 588
Description of the reference drug 589
Insulin 590
The protocol will be adapted as a function of the department's usual practice. As the insulin will be used 591 as per the marketing authorization indications and in the framework of usual follow-up, it will not be supplied by 592 the sponsor but rather will be bought in the community pharmacy. 593
Experimental drug accountability procedures 594
The clinical research assistant representing the study sponsor will check management of stocks when 595 conducting on-site monitoring visits. The study drugs will be kept in a safe, reserved access site. The contents 596 of the different drug packages will not be mixed. 597
For each patient, all information on the administration of the treatment received (date, time, dose) will be noted 598 in the paper records and in the e-CRF and in the dispensing follow-up notebook. The investigator undertakes to 599 deliver these products only to patients participating in the study and agrees to return to the sponsor, at the end 600 of the study, all original packaging, whether empty or containing unused drugs, in accordance with the 601 instructions of the study monitor. It is also agreed that the investigator will neither deliver these drugs to sites 602 nor keep them at sites other than those agreed with the sponsor. 603
Duration of the research 604
Patients with gestational diabetes requiring drug treatment will be included between 24 and 34 weeks of 605 gestation. They will take part from inclusion and treatment initiation until their child is discharged from the 606 maternity unit or the neonatal unit, ie, a maximum of 24 weeks. The total duration of the study will be 3.5 years 607 (3 years of recruitment and 24 weeks of follow-up). 608
Rules for temporary or definitive withdrawal 609
Interruption of participation in the research 610
Patients can end their participation in the research if they so wish at any time and for any reason, or as 611 decided by the investigator. This will in no way alter the quality of their subsequent healthcare. 612
Procedures for follow-up of drop-outs 613
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All drop-outs should be documented and the investigator should indicate the reason for drop-out. For 614 patients lost to follow-up, the CRF should be completed up to the last visit. The investigator will make every 615 possible effort to contact the patient and to establish the reason for her withdrawal from the trial and her state of 616 health. 617
Consequences of drop-outs 618
The patients who drop out will not be re-included in the study and their treatment numbers will not be re-619 used. These patients will be followed up in the maternity unit outside the protocol. 620
Lost to follow-up 621
The risk of patients lost to follow-up is very low because there is a small probability that a woman treated 622 for gestational diabetes will give birth in another maternity unit. The investigator will make every possible effort 623
to obtain news about the patient. 624
Discontinuation of all or part of the research 625
Only unanticipated serious adverse events in the glyburide arm of the study will be a reason to stop the 626 research. As glyburide is well known and used in diabetic patients, the likelihood of this happening is low. 627 . This diet will be combined with encouragement to do exercise 645 equivalent to 30 min of walking 3 to 5 times per week, if the patient's obstetrical condition allows. The 646 patients will be instructed concerning self-monitoring of blood glucose using glucose meters, which 647
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should have a searchable memory and comply with standard ISO 15197. During the diet, monitoring will 648 be set up as a function of the centers: self-monitoring of capillary blood glucose (4 times/day) or, after 649 10 days, fasting blood glucose and blood glucose 2 h after a meal. 650 651
The patients included are 652  Eligible patients with blood glucose targets not reached, ie, those for whom at least 2 abnormal blood 653 glucose values were noted after 10 days of well-conducted dietary management: fasting blood glucose 654 0.95 g/L and/or postprandial blood glucose at 2 h 1.20 g/L. 
Exclusion criteria 670
The discovery in a patient included of a non-inclusion criterion during the study will lead to the exclusion 671 of the patient. 672
Simultaneous participation in other research, exclusion period 673
Patients cannot take part in other research during their participation, except for the ancillary studies 674 described in section 10. 675
TREATMENTS ADMINISTERED 676
Treatments necessary for the research 677
Experimental treatment (glyburide) 678
Nature of the treatment 679
Glyburide is available as scored 5 mg tablets (Daonil®) from Sanofi Aventis. It is authorized in France for 680 the treatment of type 2 diabetes. The information leaflet is given in Appendix 18.5. 681
Modes of administration 682
Glyburide: The oral dose of glyburide will initially be 2.5 mg/day before breakfast and will be increased 683 incrementally as a function of blood glucose values up to a maximum of 20 mg/day until blood glucose targets 684 are reached (fasting blood glucose <0.95 g/L and postprandial blood glucose at 2 h <1.20 g/L). An algorithm for 685 dose adaptation depending on capillary blood glucose values will be given to the patient at the instruction 686 session. In the event of at least 2 abnormal values (fasting blood glucose 0.95 g/L and/or postprandial blood 687 glucose at 2 h 1.20 g/L), the dose will be increased by the patient at D4 to 5 mg in the morning. At D8, the 688 patient will have a review appointment with the diabetologist. If there are still 2 abnormal values, the dose will be 689 increased to 5 mg in the morning and 5 mg in the evening before dinner. At D12, if there are still 2 abnormal 690 values, the patient will increase the dose to 10 mg in the morning and 5 mg in the evening, up to a maximum 691 dose of 10 mg in the morning and 10 mg in the evening at D16. If there is a deviation from the usual diet, the 692 blood glucose value following the meal in question will not be taken into account. The patient will have a 693 diabetology appointment on D21: switch to insulin if the blood glucose targets are not reached. The patient can 694 use monitoring by telephone or by email at D4, D12 and D16 or if she experiences side effects between 695 appointments. In cases of symptomatic hypoglycemia or of blood glucose <0.6 g/L, the glyburide dose will be 696 decreased or returned to the previous level. In all cases, the alternative treatment will be insulin. 709
Reference treatment (insulin) 710
Nature of the treatment 711
The insulin treatment regimen will be adapted as a function of each department's usual practice and 712 according to capillary blood glucose values within the framework of the patient's usual treatment. 713
Methods for monitoring adherence to treatment 714
Treatment will be noted in a monitoring notebook. Capillary blood glucose values will available in this 715 notebook and also in the memory card reader. At appointments, the diabetologist and/or obstetrician can check 716 adherence to treatment using the monitoring notebook, which will be produced by the Paris Sud clinical 717 research unit. Each sheet will be in duplicate, the copy being for subsequent data entry by the clinical research 718 technician. This notebook will be kept by the patient. At each appointment, the investigator will collect the 719 completed duplicate sheets and will give them to the clinical research technician, who will then enter the data. 720 At the start of the study, the AGEPS will supply the treatment (Daonil®) to the pharmacies of the 728 participating centers. An initial stock of treatment units will be made available as a function of the number of 729 potential patients. If necessary, AGEPS will restock at the request of the participating centers' pharmacies. 730
Provision of the experimental drug
Monitoring of dispensing 731
A notebook for monitoring the dispensing of treatment will be made available for the study in each 732 pharmacy and will be completed by the clinical research assistant. 733
Insulin: 734
Dispensing: 735
The boxes of insulin will be dispensed in accordance with their marketing authorization by community 736 pharmacies or by the pharmacies of the participating centers. 737
Treatment discontinuation procedure 738
Criteria and methods for treatment discontinuation or patient exclusion 739
Glyburide will be stopped and replaced by insulin if it fails. 740
Glyburide will be replaced by insulin if it fails to achieve blood glucose targets (at least 2 abnormal blood 741 glucose values: fasting blood glucose 0.95 g/L and/or postprandial blood glucose at 2 h 1.20 g/L) for one 742 week at the maximum dose of 20 mg/day. The patients will remain in the study. 743
Data collection methods and timetable 744
The decision to stop treatment can be taken at an appointment for blood glucose monitoring or at an 745 obstetrical appointment. 746
Procedures for follow-up of drop-outs 747
All drop-outs should be documented and the investigator should indicate the reason for drop-out. For 748 patients lost to follow-up, the CRF should be completed up to the last visit. The investigator will make every 749 possible effort to contact the patient and to establish the reason for her withdrawal from the trial and her state of 750 health. 751
Consequence of drop-outs 752
Patients who drop out will not be re-included in the study and their treatment numbers will not be re-used. 753 These patients will be followed up in the maternity unit outside the protocol. 754
Modalities for replacement of drop-outs, if necessary 755
When a patient's glyburide treatment is discontinued, it will be replaced by insulin, as treatment of 756 gestational diabetes is considered necessary. Follow-up of these patients in the study will continue. 757
Modalities of follow-up of drop-outs 758
Patients who drop out will be followed up in the department, outside the protocol. In cases where there is 759 a change of treatment, follow-up of such patients will continue in the research. 760 6.4.5 Recording of refusals and exclusions 761
Patients who refuse randomization and patients who are excluded by their characteristics will also be 762 recorded (registry). 763 764
Integration of INDAO in the management of patients with gestational diabetes 765
When the blood glucose target is not reached after 10 days of well-conducted dietary management, the 766 reference treatment is subcutaneous insulin. All study outcomes and data will be recorded using the CleanWEB  e-CRF. Data on the children will be 823 collected if the previously informed parents voice no opposition. This CRF will be used by the investigator or the 824 clinical research technician to record the follow-up of patients at appointments. Data recorded will include 825 pregnancy characteristics, gestational age at diagnosis, dose of insulin or of glyburide, gestational age at 826 delivery, method of delivery, birth weight, pH at birth, 5-minute APGAR score, and all endpoints as well as the 827 reasons for any discontinuation or change of treatment. 828 A paper notebook (duplicate pages) will be used to record the patient's treatment (insulin or glyburide) and the 829 doses received. The data collected at follow-up appointments with the diabetologist and data recorded by the 830 pediatrician at birth will be entered in a paper CRF. The clinical trial technician will subsequently enter these 831 data in the e-CRF. 832 Any untoward medical occurrence that may present in a person taking part in biomedical research, 836 whether or not it has a causal relationship with the product used in the research. 837
ASSESSMENT OF SAFETY
Adverse reaction 838
Any noxious and unintended response to an experimental drug, whatever the dose administered. 
Unexpected adverse reaction to an experimental drug 844
An adverse reaction the nature, severity, or progression of which is inconsistent with the summary of 845 product characteristics, when the drug is authorized, or with the investigator brochure, when it is not authorized. 846
New finding 847
Any new safety finding that could lead to reassessment of the risk-benefit ratio of the research or of the 848 experimental drug, or which could be sufficient to envisage changes in the administration of the experimental 849 drug or in the conduct of the research. 850 This committee will comprise the clinicians who initiated the project, the biostatistician in charge of the 889 project, the clinical research unit representative appointed for this research, and the department of clinical 890 research and development representative. It will define the general research organization and procedures and 891 will coordinate data. It will initially determine the methodology and, during the research, will decide how to deal 892 with unforeseen situations and will monitor the research, in terms of safety and adverse events, in particular. 893
Adverse reactions to treatment
Scientific committee 894
This committee will comprise those who helped draw up and write the protocol. It will be consulted during the 895 trial to take stock of progress and for analysis of the results. 896
Independent monitoring committee 897
This committee will comprise a group of experts who supervise the clinical trial data concerning the safety 898 of patients and the efficacy of treatment. Notably, the committee will be in charge of monitoring any severe 899 adverse effects that occur. The committee can recommend discontinuation of the trial following evaluation of the 900 results. It can also decide to stop the trial for reasons of patient safety, inefficacy compared with the reference 901 treatment, or a clinical benefit much greater than that of the reference treatment. This independent committee 902 will meet periodically to assess progress, safety data, and determinant events in terms of efficacy. adverse event. Should the death of a participant occur during the research, the investigator will send the 925 sponsor all additional information requested (hospital report, autopsy findings, etc.). 926
The sponsor must be informed of any new finding in the research or in the context of the research, 927 provided by the research itself or from the scientific literature. 928 -Reporting of serious adverse events to the health authorities 929
The pharmacovigilance unit of the clinical research and development department will report serious 930 adverse events to the health authorities, after evaluation of their seriousness, the causal relationship with the 931 experimental drug, with insulin, and with any other treatments, and the unexpected nature of the adverse 932 events. The sponsor will notify the appropriate health authorities of any suspected unexpected serious adverse 933 event within the legally stipulated timeframe. Any safety data or new finding that could significantly affect the 934 evaluation of the risk-benefit ratio of the experimental drug, or of the research, or which could lead to changes 935 concerning the administration of the drug or the conduct of the research, will be sent by the sponsor to the 936 appropriate health authorities, the ethics committee, and the study investigators. 937 938
Modalities and duration of follow-up of patients after adverse events 939
Any patient presenting an adverse event must be followed up until the event is resolved or stabilized.
940
-If the event is not serious, progress will be noted on the corresponding page of the CRF in the section 941 provided for the purpose.
942
-If the event is serious, a serious adverse event follow-up report will be sent to the clinical research and 943 development department. 944
STATISTICS
945
Data analysis 946
Data will be entered progressively as the trial advances, overseen by the investigator, using CleanWEB Bouyer. 951
The glyburide group will be compared with the insulin group in terms of the patients' demographic, 952 obstetrical, and medical characteristics. The glyburide and insulin groups will be compared in terms of the 953 composite endpoint (primary study outcome) by calculating the confidence interval of the percentage difference 954 between the 2 groups. It will be concluded that glyburide treatment is not inferior to insulin therapy if this 955 confidence interval does not contain the value 7%, which has been selected as the limit of equivalence. 956
If, despite randomization, the 2 groups are unbalanced for one or more demographic, obstetrical, or 957 medical variables, an adjustment will be made by logistic regression [44] . All tests and confidence intervals will 958 be done with a 5% risk of error. 959
The usual recommendations for a clinical trial are an intention to treat analysis [45] . However, for a noninferiority 960 trial this type of analysis can reduce the apparent deviation between the treatments and so incorrectly indicate 961 noninferiority. A per protocol analysis is therefore recommended. Both analyses will be done because they yield 962 complementary information. More weight will be given to the per protocol analysis. The results will be all the 963 more convincing if the results of the 2 types of analysis agree. 964
It was decided not to perform interim statistical analyses because this would require an increase in the number 965 of subjects included. 966
Planned number of people to be included in the research 967
The number of subjects needed was calculated using the primary outcome. 25% with glyburide (when it is 18% with insulin). To guarantee a power of 80% (with a 5% threshold of 978 significance), we therefore need 372 subjects per group. In considering that about 20% of the patients treated 979 with glyburide will not reach the defined blood glucose targets and will be switched to insulin, 450 subjects per 980 group will be necessary. 981
The estimated percentage of pregnant women with gestational diabetes who require drug treatment is 982 1.5%, so 60 000 pregnant women will be necessary. Assuming that one in 2 women will agree to randomization, 983
we need a population of 120 000 pregnant women. Given that the participating maternity units manage about 984 40 000 deliveries per year, recruitment should be complete in 3 years. 985
The distribution of subjects per center is not fixed and will depend on recruitment, which is a function of the 986 number of pregnant women followed up and the real percentage of acceptance of the trial by the patients. The 987 only restriction is the balance between the groups in each center, which is ensured by the fact that the 988 randomization is stratified by center. 989
Missing data 990
If necessary, the characteristics of patients lost to follow-up will be studied and compared with those of the 991 patients who are followed up. A sensitivity analysis will be used to determine to what extent the results of the 992 study may have been influenced by this lack of information. 993
In cases of missing data, the analysis will be done using the classic complete-case method, ie, by considering 994 only subjects without missing data. Multiple imputation methods can also be used as an analysis of sensitivity 995 as, even if the methodology is under development, the assumptions of these methods are less strong than 996 those of the complete-case analysis. 997 
Choice of patients to be included in the analysis
